Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
or

Spruce Biosciences Inc (SPRB)

Spruce Biosciences Inc (SPRB)
0.1311 x 50 0.1380 x 1
Post-market by (Cboe BZX)
0.1399 +0.0070 (+5.27%) 04/24/25 [NASDAQ]
0.1311 x 50 0.1380 x 1
Post-market 0.1379 -0.0020 (-1.43%) 18:53 ET
News & Headlines for Thu, Apr 24th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
S&P Futures Climb Ahead of Key U.S. PPI and Retail Sales Data, Adobe Earnings on Tap

March S&P 500 E-Mini futures (ESH24) are trending up +0.37% this morning as market participants geared up for crucial U.S. PPI and retail sales data while also awaiting quarterly results from software...

PATH : 11.32 (+4.14%)
DG : 93.81 (-1.70%)
ULTA : 385.93 (+2.17%)
C : 68.16 (+2.81%)
FSR : 0.0897 (-28.13%)
DLTR : 81.23 (-2.64%)
SPRB : 0.1399 (+5.27%)
DKS : 189.51 (+2.80%)
ESH24 : 5,101.67s (-1.01%)
ECV.D.DX : 18.040 (+3.14%)
TSLA : 259.51 (+3.50%)
SDF.D.DX : 14.080 (+1.29%)
S&P Futures Tick Higher as Investors Weigh Interest Rate Outlook

September S&P 500 futures (ESU23) are trending up +0.08% this morning after the S&P 500 and Nasdaq closed in the red on Thursday as technology stocks dropped on concerns over the outlook for Apple, while...

AAPL : 208.37 (+1.84%)
AI : 22.02 (+7.99%)
CCC.LN : 2,360.000 (+1.46%)
SWKS : 61.50 (+4.84%)
SPRB : 0.1399 (+5.27%)
SWBI : 9.60 (+0.31%)
SMAR : 56.47 (+0.02%)
MCD : 316.22 (-0.71%)
FSLR : 136.44 (+4.07%)
QCOM : 147.21 (+4.81%)
INTC : 21.49 (+4.37%)
ADBE : 360.91 (+2.54%)
Spruce Biosciences to Present Findings on Retrospective Analysis of Completion Rates for CAH Studies at Pediatric Endocrine Society 2023 Annual Meeting

Spruce Biosciences, Inc . (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need,...

SPRB : 0.1399 (+5.27%)
Spruce Biosciences to Participate in May Investor Conferences

Spruce Biosciences, Inc . (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need,...

SPRB : 0.1399 (+5.27%)
Spruce Biosciences Reports Full Year 2022 Financial Results and Provides Corporate Updates

Spruce Biosciences, Inc . (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need,...

SPRB : 0.1399 (+5.27%)
Spruce Biosciences to Participate in the Oppenheimer 33rd Annual Healthcare Conference

Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need,...

SPRB : 0.1399 (+5.27%)
Spruce Biosciences Announces $53.6 Million Private Placement Financing

Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need,...

SPRB : 0.1399 (+5.27%)
Spruce Biosciences to Participate in the SVB Securities Global Biopharma Conference

Spruce Biosciences, Inc . (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need,...

SPRB : 0.1399 (+5.27%)
Spruce Biosciences Provides Clinical Program Updates and Outlines Anticipated Milestones for 2023

Spruce Biosciences, Inc . (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need,...

SPRB : 0.1399 (+5.27%)
Spruce Biosciences (NASDAQ: SPRB) Enters Into Collaboration with Kaken Pharmaceutical to Develop Tildacerfont for CAH in Japan

Spruce Biosciences, Inc. (NASDAQ: SPRB) is engaged as a late-stage biopharmaceutical company, which is focused on the research, development and

SPRB : 0.1399 (+5.27%)

Barchart Exclusives

Grain Rally Mystery: Why Are Soybeans, Corn, and Wheat Bucking the Trend?
In an interview on AgWeb's Markets Now, Darin Newsom of Barchart discussed the surprising grain market rally led by soybeans despite negative China trade news, a potential corrective bounce in corn with weak basis, and a likely bear trap in wheat, while also touching on the bullish cattle market's connection to equities and a potential shift out of stocks into safer assets. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Value Investing Philosophies: Graham, Buffett, Bogle, and EMH in Perspective